Bal Pharma Ltd (BALPHARMA) is currently trading at 81.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bal Pharma Limited is an Indian pharmaceutical manufacturer and marketer of formulations and APIs, operating manufacturing units and multiple subsidiaries focused on formulations, bulk drugs and analytical research, with product launches across therapeutic areas and a growing integrated API footprint built to support both domestic formulations and bulk drug production. Financially, Bal Pharma reported consolidated revenue from operations of Rs. 8,768.97 lakhs for Q3 (Dec-25) and Rs. 22,759.55 lakhs for the nine months ended Dec-25, with modest profitability — consolidated quarterly net profit of Rs. 179.06 lakhs and nine-month profit of Rs. 271.63 lakhs; results were reviewed with an unmodified auditor opinion. Strategically, Bal Pharma has completed or initiated several transformative moves: a 270 MT integrated API unit at Gauribidanur, acquisition of Golden Drugs Private Limited in 2017-18, earmarking Rs. 36 crore for a Yadgir bulk-drugs plant in 2022-23, and the 2023 launch of Sitagliptin and fixed-dose combinations, signalling a push up the value chain into APIs and specialty formulations. Operationally, Bal Pharma manufactures in Uttarakhand, Gauribidanur and through the acquired Udaipur facility, sells a broad product range including branded formulations, and has subsidiaries in healthcare services and research; management notes intent to transition from a common group sales force to an independent sales force for Bal Pharma products.

Over the past 52 weeks, Bal Pharma Ltd has traded between a low of ₹59.69 and a high of ₹124.68. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bal Pharma Ltd has a market capitalization of approximately 129.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.92 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 129.91 Cr, Bal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bal Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bal Pharma Ltd is 17.92. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The corrigendum revised the convertible warrant issue price to ₹84 per warrant from ₹81, increasing the cited potential capital raise to ₹8.4 crore.